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204 Crohn’s disease [59.3%]). Drug regimens applied in the year before index hospitalization were as
follows: no IBD drugs (43.6% ulcerative colitis, 43.1% Crohn’s disease); 5-ASA (45.7% ulcerative colitis,
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Background
Inflammatory bowel diseases (IBD) are chronic disabling 
disorders characterized by chronic inflammation of the 
gastrointestinal tract. Ulcerative colitis and Crohn’s dis-
ease represent the two main forms of IBD. IBD seems to 
evolve in genetically susceptible individuals based on a 
dysbalanced gastrointestinal immune system that reacts 
inappropriately to microbes of the gastrointestinal tract 
[1]. Prevalence estimates range between 0.3 and 0.5%, 
and are higher in Western industrialized countries [2,3]. 
Prevalence and incidence of IBD have increased in many, 
predominantly industrialized, countries [4]. IBD may not 
only be limited to the gastrointestinal tract, patients may 
suffer also from associated comorbidities such as extrain-
testinal manifestations (arthralgias, skin manifestations 
such as erythema nodosum or psoriasis, etc.) [5,6]. These 
IBD-associated comorbidities may increase health resource 
utilization in terms of outpatient consultations, diagnostic 
procedures, therapeutic modalities (e.g., drug regimens), 
hospitalizations, and need for surgeries [7–9]. In a recently 
studied cohort of 4791 Swiss IBD patients, 78% had at 
least one comorbidity with a median of three chronic 
conditions [10]. The most prevalent chronic comorbidi-
ties were cardiovascular diseases (41.4%), rheumatologic 
conditions (36.3%), acid-related disorders (26.5%), and 
pain (25.8%) [10].
A recently published study from the Swiss IBD Cohort 
found that almost 14% of IBD patients were hospitalized 
for at least one day during a 12-month follow-up [11]. As 
of yet, no data is available regarding therapeutic strate-
gies and healthcare usage in the 12 months before an IBD-
related hospitalization. The assessment of these factors is 
important in order to understand if suboptimal therapeu-
tic strategies and monitoring of IBD patients contribute to 
the consecutive IBD-related hospitalization.
Healthcare claims data from insurance groups are 
very useful tools to evaluate prescribed drugs and health 
resource utilization for IBD patients in Switzerland. The 
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claims data are reliable, practice-based and provide a high 
level of completeness that is independent of the insurance 
coverage. The Helsana Group covers a relatively large 
and geographically diverse part of the Swiss population. 
Our research group has recently published on the health 
resource utilization in IBD outpatients [12]. In outpa-
tients, the discrimination between Crohn’s disease and 
ulcerative colitis is not possible when analyzing health 
insurance claims data.
We conducted this study to evaluate the drug therapy 
patterns, health resource utilization, and the associated 
costs in the 12-month period preceding hospitalization.
Methods
Study design
This is a retrospective cohort study of patients with IBD 
who were hospitalized in the period from 1 January 2013 
to 31 December 2015. Patients were followed during a 
12-month period before being hospitalized due to an IBD 
flare (day 365 of the evaluation period corresponds to 
the day before the IBD-related hospitalization). Health 
resource utilization was assessed during the 12-month 
period before the hospitalization and costs were calcu-
lated for outpatient treatment, stratified into costs for pri-
mary care, specialist care, drugs (IBD related and non-IBD 
related), laboratory examinations, and others (paramedi-
cal visits, home care nursing services, and use of medical 
devices).
The study complies with Swiss federal legislation. All 
data were anonymized, retrospective, preexisting, and 
deidentified in order to protect the privacy of patients, 
physicians, and hospitals. Therefore, no ethics committee 
approval was necessary for this study.
Study population
The Helsana database underlying this study included 
mandatory health insurance claims from approximately 
1.2 million persons per year, covering about 15% of the 
entire Swiss population (which counts currently about 
8 million inhabitants). We identified 513 patients aged 
18 years and older with at least one IBD-related hospital-
ization between 1 January 2013 and 31 December 2015.
Patients with a preceding hospitalization during the 
12 months before the IBD-related index hospitalization 
(n = 139), deceased patients (n = 21), asylum seekers (n = 3), 
as well as individuals who dropped out of the Helsana 
Group during the 1-year evaluation period (n = 6) were 
excluded in order to have the complete data for the given 
observation time. Of the 344 IBD patients included in the 
final sample, 140 (57.2%) had ulcerative colitis and 204 
patients (42.8%) had Crohn’s disease.
Measures
Since 2012, Switzerland has introduced a ‘diagnosis-re-
lated group’ system, which refers to ICD-10 codes and 
applied procedures. As such, IBD patients were identi-
fied using the ICD-10 codes K50 and K51, respectively. 
Further population characteristics were used as covariates. 
They included sex, age group (18–40, 41–60, 61+), addi-
tional chronic conditions, language area, type of insurance 
coverage (managed care model, supplementary hospital 
insurance, and deductible class), type of residence, as well 
as having had surgery at index hospitalization [13].
In Switzerland, health insurance is mandatory for 
each citizen and is based on a cost sharing compulsory 
basic coverage for each resident consisting of co-pay-
ments and deductibles. The height of the deductible can 
to some extent be chosen by the policy holder, whereby 
higher deductibles lead to lower monthly payments to 
the health insurance. Deductibles range from EUR 250 to 
2060, whereby deductibles higher than EUR 410 belong 
to the higher deductible class for the purpose of this arti-
cle. Co-payments amount to 10% of the yearly health care 
costs and are limited to EUR 580 per person per year.
Drugs applied
Following the concept of the therapeutic pyramid in IBD 
patients, we defined the following steps [14,15]:
1. 5-aminosalicylic acid (mesalazine and sulfasalazine)
2. Locally active corticosteroids (budesonide)
3. Systemic corticosteroids (prednisone)
4. Immunomodulators (thiopurines, methotrexate)
5. Biologics (Tumor necrosis factor alpha (TNF) antag-
onists: adalimumab, infliximab, golimumab, certoli-
zumab-pegol; integrin inhibitors: vedolizumab)
6. Others (calcineurin inhibitors: tacrolimus).
Healthcare costs
We aimed to determine the economic burden of hospital-
ized IBD patients from a social insurance payer perspective 
including all type of direct health care costs (i.e., tax-
funded costs are excluded). Annual total healthcare costs 
in IBD patients in the year before index hospitalization in 
the time period from 1 January 2013 to 31 December 2015 
were obtained from providers’ claims and defined as the 
total amount of outpatient costs per patient per 12-month 
period with mandatory insurance coverage. Costs were 
not limited to an IBD indication. As such, costs for IBD-
associated comorbidities such as rheumatologic manifesta-
tions are included in the analysis. Costs from the outpatient 
setting comprised payments for office-based physician vis-
its (primary care physician and specialists), hospital outpa-
tient visits, paramedical visits (e.g., physiotherapists), home 
care nursing services, medications, diagnostic procedures 
(laboratory tests, imaging), and medical devices.
All costs are converted and quoted in Euros (1 
CHF = 0.824 EUR; effective 30 June 2014). Outpatient 
costs are covered by the health insurance, inpatient costs 
to a share between 45 and 55% (depending on the canton 
and calendar year). Out-of-pocket payments, depending 
on the chosen premium, could not be considered, because 
they are not covered by the compulsory health insurance.
Healthcare utilization
Outpatient visits were not limited to an IBD indication. 
Visits were defined as direct contacts between patient and 
physician (including home visits). As such, visits for treat-
ment with TNF antagonists were also considered to be 
medical visits if a face-to-face contact with a physician 
took place. The following supplementary measures are 
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provided as outpatient visits in the 1-year observation 
period: the total number of outpatient visits, the number of 
primary care physician and specialist visits (stratified into 
gastroenterologists, including hospital outpatient visits, 
and other specialists), as well as the proportion of patients 
without any gastroenterologist visit in the look-back 
period. We performed a detailed analysis of IBD-related 
drugs used in the observation interval. Furthermore, we 
evaluated the frequency and costs of tools for diagnosis 
and monitoring of IBD, such as abdominal computed 
tomography (CT) scanning, abdominal and/or pelvic MRI 
examinations, radiograph examinations, abdominal ultra-
sounds, endoscopies, and fecal calprotectin.
Statistical analysis
Bivariate descriptive statistics were used to show differ-
ences between the characteristics of individuals with either 
Crohn’s disease or ulcerative colitis using Fisher’s exact 
test for dichotomous variables, Wilcoxon rank sum test 
for continuous, and Chi-squared test for categorical varia-
bles. Direct healthcare costs and healthcare utilization are 
presented overall and then stratified according to Crohn’s 
disease or ulcerative colitis diagnosis.
Treatment with IBD-specific drugs in the year before 
hospitalization was analyzed using transversal state dis-
tribution plots and stacked bar charts, both following the 
concept of the therapeutic pyramid in IBD (see chapter 
methods, drugs applied) [15,16]. Furthermore, we used 
line plots of smoothed data (where the smoothing method 
was local polynomial regression fitting) to show temporal 
changes in drug prescriptions. All analyses were carried 
out using R, version 3.2.0 (R Core Team. R: A Language 
and Environment for Statistical Computing. 2015. http://
www.R-project.org/) [17].
Results
Patient characteristics and drugs used in the year 
before hospitalization
The baseline characteristics of the 344 patients are shown 
in Table 1. When compared with ulcerative colitis patients, 
Crohn’s disease patients were younger (median 45 vs 
61 years, P < 0.001), they had less comorbid conditions 
(P = 0.003), and they underwent significantly more fre-
quently an IBD-related surgical intervention at index hos-
pitalization (26.0 vs 7.1%, P < 0.001).
The drugs used during the 1-year period prior to 
hospitalization are shown in Table  2. A total of 43.3% 
of patients did not have any IBD-related drugs, with no 
difference being observed between ulcerative colitis and 
Crohn’s disease patients. When compared with ulcera-
tive colitis patients, Crohn’s disease patients were signifi-
cantly less frequently treated with 5-ASA (19.1 vs 45.7%, 
P < 0.001), and they received more frequently anti-TNF 
drugs (24.0 vs 9.3%, P < 0.001). Following the concept 
of the therapeutic pyramid, we evaluated which ‘highest’ 
drug category was applied in the year prior to hospitali-
zation (Supplementary Table 1, Supplemental digital con-
tent 1, http://links.lww.com/EJGH/A484). We observed a 
significant overall difference between Crohn’s disease and 
ulcerative colitis patients. When compared with ulcerative 
colitis patients, Crohn’s disease patients more frequently 
received biologic therapies. The proportion of ulcerative 
colitis and Crohn’s disease patients who were treated 
with an IBD-related drug, following again the principle 
of the therapeutic pyramid, is shown in Fig. 1. Figure 1 
demonstrates the large proportion of Crohn’s disease and 
ulcerative colitis patients without any IBD-specific drug 
during the year before the hospitalization. 5-ASA only was 
used much more frequently in ulcerative colitis patients 
compared with Crohn’s disease patients. Steroids as the 
‘highest’ drug category, in combination with 5-ASA, were 
found more frequently in ulcerative colitis compared with 
Crohn’s disease patients. Compared with ulcerative colitis 
patients, Crohn’s disease patients more often had a step-up 
to biologic therapies. Figure 2 provides a detailed analysis 
of the prescription pattern of the distinct IBD-specific drugs 
during the year before hospitalization, stratified according 
to IBD diagnosis. A mild increase in 5-ASA prescriptions 
was observed in the last 3 months before hospitalization in 
Crohn’s disease patients, while this increase was marked in 
ulcerative colitis patients. A similar pattern was observed 
for the prescription of steroids, again with a mild increase 
for Crohn’s disease patients in the months before hospi-
talization which was contrasted by a marked increase for 
ulcerative colitis patients. The prescription of immuno-
modulators was relatively constant from month 12 to 4 
Table 1. Baseline characteristics of included patients (n = 344)
Total IBD Ulcerative colitis patients Crohn’s disease patients P value
n 344 140 (40.7%) 204 (59.3%)  
Female sex 185 (53.8%) 81 (57.9%) 104 (51.0%) ns
Age (years, median, first-third quartile) 49 (33, 69) 61 (36, 74) 45 (31, 62) <0.001
Age groups (years)    <0.001
 18–40 127 (36.9%) 42 (30.0%) 85 (41.7%)  
 41–60 92 (26.7%) 27 (19.3%) 65 (31.9%)  
 60+ 125 (36.3%) 71 (50.7%) 54 (26.5%)  
Type of residence (urban) 269 (78.2%) 106 (75.7%) 163 (79.9%) ns
French/Italian (vs German) region 76 (22.1%) 30 (21.4%) 46 (22.5%) ns
Chronic conditions [mean, median (first–third quartile)] 2.4, 2.0 (1.0–4.0) 2.8, 2.0 (1.0–4.0) 2.1, 2.0 (1.0–3.0) 0.003
Health insurance plan
 Managed care 159 (46.2%) 74 (52.9%) 85 (41.7%) 0.047
 Higher deductible 43 (12.5%) 13 (9.3%) 30 (14.7%) ns
 Supplementary hospital insurance 58 (16.9%) 25 (17.9%) 33 (16.2%) ns
Surgery at index hospitalization 63 (18.3%) 10 (7.1%) 53 (26.0%) <0.001
P values, assigning the differences between ulcerative colitis and Crohn’s disease, were calculated using fisher’s exact test for dichotomous variables, Wilcoxon 
rank sum test for continuous, and Chi-squared test for categorical variables.
IBD, inflammatory bowel disease; ns, not significant.
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Table 2. Drugs used by inflammatory bowel disease patients during the one-year follow period prior to the inflammatory bowel disease-related 
hospitalization
Total IBD Ulcerative colitis patients Crohn’s disease patients P value
n 344 140 (40.7%) 204 (59.3%)  
No IBD-related drugs 149 (43.3%) 61 (43.6%) 88 (43.1%) ns
5-ASA 103 (29.9%) 64 (45.7%) 39 (19.1%) <0.001
Steroids (total) 143 (41.6%) 65 (46.4%) 78 (38.2%) ns
 Systemic 114 (33.1%) 54 (38.6%) 60 (29.4%) ns
 Local 61 (17.7%) 25 (17.9%) 36 (17.6%) ns
Immunmodulators 52 (15.1%) 15 (10.7%) 37 (18.1%) ns
TNF antagonists (TNF) 62 (18.0%) 13 (9.3%) 49 (24.0%) <0.001
Integrin inhibitors 1 (0.3%) 1 (0.7%) 0 (0%) na
Biologics (TNF + INT) 63 (18.3%) 14 (10.0%) 49 (24.0%) 0.001
Calcineurin inhibitors 6 (1.7%) 3 (2.1%) 3 (1.5%) na
P values, assigning the differences between ulcerative colitis and Crohn’s disease, were calculated using fisher’s exact test.
IBD, inflammatory bowel disease; INT, integrin inhibitors; na, not applicable related to small sample size; ns, not significant; TNF, tumor necrosis factor alpha.
Fig. 1. Proportion of ulcerative colitis and Crohn’s disease patients with an IBD-related drug in the year before IBD-related hospitalization. 5-ASA, aminosa-
licylates; Bio, biologics; IBD, inflammatory bowel disease; IM, immunomodulators; Ster, steroids.
Fig. 2. Proportion of ulcerative colitis and Crohn’s disease patients with an IBD-related drug in the 12-month period before hospitalization. IBD, inflamma-
tory bowel disease.
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before hospitalization, whereas it gradually increased for 
both ulcerative colitis and Crohn’s disease in the 3 months 
before hospitalization. Biologic use was characterized by 
a gradual increase with a plateau at 3 months before hos-
pitalization in Crohn’s disease patients compared with a 
peak in ulcerative colitis patients at month 4 before hos-
pitalization, but then a steep decrease in the last 3 months 
before hospitalization.
Compared with patients not undergoing surgery at 
index hospitalization, IBD patients with surgery were sig-
nificantly more often treated with local steroids (25.4 vs 
16.0%, P = 0.047), immunomodulators (33.3 vs 11.0%, 
P < 0.001), and biological therapy (39.7 vs 13.5%, 
P < 0.001) in the 12 months prior to hospitalization.
The healthcare plan (managed care, basic insurance, 
and supplementary insurance) had no influence on the fre-
quency of prescribed IBD drugs in the 12 months prior to 
hospitalization, with the expection of 5-ASA in Crohn’s dis-
ease patients which were found significantly less frequently 
in patients with managed care plan compared with patients 
with basic health insurance (11.8 vs 24.4%, P = 0.030).
We further analyzed the drug prescription patterns 
stratified according to the observation if patients had 
at least one visit with a gastroenterologist in the last 
3 months before the hospitalization. Supplementary Fig. 
1, Supplemental digital content 2, http://links.lww.com/
EJGH/A485 shows indeed that the 52.9% of ulcerative 
colitis patients who had at least one visit with a gastro-
enterologist within the last 3 months before the hospitali-
zation were characterized by a much higher frequency of 
prescription of IBD-specific drugs when compared with 
ulcerative colitis patients who did not have a visit with 
a gastroenterologist within the last 3 months before the 
hospitalization. A marked increase in the prescription 
of 5-ASA, steroids, and immunomodulators in the last 
3 months before hospitalization could be observed for 
patients who consulted a gastroenterologist, while biologic 
treatment was more frequent in these patients throughout 
the 1-year observation period.
Supplementary Fig. 2, Supplemental digital content 3, 
http://links.lww.com/EJGH/A486 shows the IBD-specific 
drug prescriptions in the year before hospitalization in the 
59.8% of Crohn’s disease patients who had at least one 
visit with a gastroenterologist within the last 3 months 
before the hospitalization compared with the group 
without a visit with a gastroenterologist. Crohn’s disease 
patients with at least one visit to the gastroenterologist in 
the last 3 months prior to hospitalization were prescribed 
significantly more frequently steroids, immunomodulators, 
and biologics when compared to their counterparts, with 
no significant difference regarding 5-ASA prescriptions. 
Similar to the observation in ulcerative colitis patients, a 
gradual increase in the prescription of IBD-specific drugs 
was observed over time.
Diagnostic procedures in the year before hospitalization
The frequencies of abdominal CT scanning, abdominal 
and/or pelvic MRI examinations, radiograph examina-
tions, abdominal ultrasounds, colonoscopies, as well as 
calprotectin measurements in the 12-months look-back 
period are shown in Table  3. A total of 36.9% of IBD 
patients had no diagnostic procedures at all in the year 
before hospitalization. Diagnostic procedures (endos-
copy/sonography and/or fecal calprotectin) were signifi-
cantly more often performed in Crohn’s disease patients 
compared with ulcerative colitis patients (65.7 vs 50.7%, 
P = 0.007). We further evaluated if there is a difference in 
diagnostic procedures with regards to therapy with IBD-
specific drugs. When comparing ulcerative colitis patients 
who received IBD drug treatment in the 12 months before 
hospitalization with ulcerative colitis patients with-
out IBD drug treatment, we found that ulcerative colitis 
patients under IBD drugs underwent significantly more 
often diagnostic procedures (75.9 vs 27.9%, P < 0.001, 
Supplementary Table 2, Supplemental digital content 1, 
http://links.lww.com/EJGH/A484). The same was found 
for Crohn’s disease patients where 86.2% of patients 
under IBD drugs underwent diagnostic procedures com-
pared with 45.5% of patients without IBD drug treatment 
(P < 0.001, Supplementary Table 3, Supplemental digital 
content 1, http://links.lww.com/EJGH/A484).
We further evaluated the concordance between the 
patients without any diagnostic procedures and patients 
who did not receive any IBD-specific treatment in order 
to assess if both populations are identical. Of the 36.9% 
of patients without any diagnostic procedures, 72.4% did 
not receive any IBD-specific drugs. On the other hand, 
out of the 43.3% of patients without IBD-specific drugs, 
a total of 61.7% did not undergo a diagnostic procedure. 
As such we can conclude that both groups have a relevant 
overlap but they are not identical (Cramer’s V of 0.450 
which is regarded as moderate association).
Consultations in ulcerative colitis and Crohn’s disease 
patients
We further analyzed the number of face-to-face con-
sultations in the one-year period before hospitaliza-
tion (Table  4). The median number of face-to-face 
Table 3. Diagnostic procedures in ulcerative colitis and Crohn’s disease patients in the year before hospitalization
Total IBD ulcerative colitis patients Crohn’s disease patients P value
n 344 140 (40.7%) 204 (59.3%)  
No diagnostic procedures 127 (36.9%) 63 (45.0%) 64 (31.4%) 0.012
CT 45 (13.1%) 12 (8.6%) 33 (16.2%) ns
MRI 44 (12.8%) 5 (3.6%) 39 (19.1%) <0.001
Radiograph 8 (2.3%) 3 (2.1%) 5 (2.5%) na
Sonography 126 (36.6%) 40 (28.6%) 86 (42.2%) 0.012
Colonoscopy 121 (35.2%) 43 (30.7%) 78 (38.2%) ns
Calprotectin 91 (26.5%) 24 (17.1%) 67 (32.8%) 0.001
Endoscopy/Sonography/Calprotectin 205 (59.6%) 71 (50.7%) 134 (65.7%) 0.007
P values, assigning the differences between ulcerative colitis and Crohn’s disease, were calculated using fisher’s exact test.
CT, computed tomography; IBD, inflammatory bowel disease; na, not applicable; ns, not significant.
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consultations was 13.5 (interquartile range (IQR) 7–22), 
of which a median of 5 (IQR 1–10) consultations were 
provided by primary care physicians and a median of 3 
(IQR 0–9) consultations by gastroenterologists. In bivar-
iate analyses, the number of consultations was not differ-
ent between Crohn’s disease and ulcerative colitis patients, 
except for visits to primary care physicians. We further 
evaluated the number of consultations stratified according 
to IBD diagnosis and according to the fact if patients were 
treated with IBD-specific drugs or not. When compared 
with ulcerative colitis patients without IBD drugs, ulcer-
ative colitis patients under IBD drugs significantly more 
frequently had consultations by any physician (median 
16 vs 11, P = 0.002), and consultations by a gastroenter-
ologist (median 5 vs. 1, P < 0.001, Supplementary Table 
4, Supplemental digital content 1, http://links.lww.com/
EJGH/A484). Similar results were observed in Crohn’s 
disease patients (Supplementary Table 5, Supplemental 
digital content 1, http://links.lww.com/EJGH/A484), 
where patients under IBD drugs significantly more fre-
quently had consultations by any physician (median 17 
vs. 8, P < 0.001), and consultations by a gastroenterologist 
(median 8 vs. 1, P < 0.001).
Costs in ulcerative colitis and Crohn’s disease patients 
in the year prior to hospitalization
We further evaluated the total costs of healthcare utili-
zation during the year prior to hospitalization (Table 5). 
In the unadjusted bivariate analysis, the median annual 
outpatient costs per IBD patient were EUR 4320 with 
almost equal costs for Crohn’s disease and ulcerative coli-
tis patients. Costs for specialist consultations were higher 
compared with the costs for primary care. Drug costs 
accounted for roughly 30% of the outpatient costs with-
out any difference between ulcerative colitis and Crohn’s 
disease patients. Interestingly, the majority of drug costs 
was associated with non-IBD-related drugs whereas IBD-
related drug costs accounted for less than 10% of the 
median drug costs.
Discussion
This is the first population-based in-depth study that 
examines the drug prescription patterns, health resource 
utilization, and costs reimbursed by basic health insurance 
during a 12-month period before an IBD-related index 
hospitalization. Our analysis contains several clinically 
relevant messages. First, 43% of IBD patients were not 
treated with IBD-specific drugs in the observation period 
and 37% of these patients did not undergo any diagnostic 
procedures. Second, patients being followed by gastroen-
terologists had significantly more frequent treatment with 
IBD-specific drugs when compared with patients followed 
by primary care physicians. Third, prescription of IBD-
specific drugs increased in frequency during the three 
months before IBD-related hospitalization. We observed 
relevant differences between ulcerative colitis and Crohn’s 
disease patients regarding the drug prescription patterns 
with immunomodulators and biologic therapy being more 
frequently used in Crohn’s disease patients compared with 
ulcerative colitis patients. And last, median outpatient 
costs in the 12-month observation period were similar in 
both diseases with about EUR 4300.
The first key finding is that roughly 40% of IBD patients 
were neither treated with IBD-specific drugs nor did they 
undergo any diagnostic or follow-up procedure in the 12 
months before IBD-related hospitalization. Several rea-
sons might explain this finding. The first reason might be 
that patients were diagnosed with IBD only during hospi-
talization. In fact, diagnostic delay has been identified as 
a common problem in IBD. In Switzerland, median diag-
nostic delay was determined to be 9 months for Crohn’s 
disease patients compared with 4 months for patients with 
ulcerative colitis [18]. Timely diagnosis of IBD is relevant 
not only to decrease suffering on patient’s side but also 
to decrease the risk of bowel damage that is associated 
with increased risk of intestinal surgery in Crohn’s disease 
patients [19]. The Swiss findings have been corroborated 
by several other studies [20,21]. The broader use of fecal 
calprotectin among healthcare practitioners might have 
Table 4. Consultations in ulcerative colitis and Crohn’s disease patients in the year before hospitalization
Consultations (median, first–third quartile) Total IBD ulcerative colitis patients Crohn’s disease patients P value
n 344 140 (40.7%) 204 (59.3%)  
Face-to-face consultations 13.5 (7.0–22.0) 15.0 (7.0–22.5) 12.5 (7.0–22.0) ns
 By primary care physicians 5.0 (1.0–10.0) 6.0 (3.0–11.0) 4.0 (1.0–9.0) 0.002
 By gastroenterologists 3.0 (0–9.0) 2.5 (0–7.0) 3.0 (0–10.0) ns
 By other specialists 1.0 (0–5.0) 1.0 (0–5.0) 1.0 (0–4.25) ns
Patients (%) without any visit by gastroenterologists in look-back 96 (27.9%) 41 (29.3%) 55 (27.0%) ns
P values, assigning the differences between ulcerative colitis and Crohn’s disease, were calculated using Wilcoxon rank sum test.
IBD, inflammatory bowel disease; na, not applicable; ns, not significant.
Table 5. Healthcare costs (in EUR) in ulcerative colitis and Crohn’s disease patients in the year before hospitalization
Costs (median, first–third quartile) Total IBD ulcerative colitis patients Crohn’s disease patients P value
Outpatient 4320 (1910–11 890) 4060 (2360–7390) 4900 (1520–14 880) ns
 Primary care 360 (110–690) 430 (190–790) 290 (30–610) 0.003
 Specialists 1370 (330–2650) 1220 (320–2300) 1600 (350–2780) ns
 Medications 1300 (400–4080) 1280 (580–2920) 1310 (310–8880) ns
 Laboratory 390 (150–850) 380 (130–770) 410 (150–930) ns
 Others 50 (0–370) 70 (0–540) 40 (0–270) ns
P values, assigning the differences between ulcerative colitis and Crohn’s disease, were calculated using Wilcoxon rank sum test; other costs include costs 
incurred by paramedical visits (e.g., physiotherapists), home care nursing services and by use of medical devices.
ns, not significant
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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the potential to reduce diagnostic delay in IBD patients 
[22]. Another reason for not receiving IBD-specific treat-
ment could be IBD patients could have been asympto-
matic in the year before IBD-related hospitalization and 
treating physicians might have seen no necessity for treat-
ment and/or diagnostic procedures. Furthermore, patients 
might have been nonadherent to the prescription of IBD-
specific drugs. In fact, nonadherence has been identified 
as a relevant problem in IBD. A threshold of following 
treatment advice for at least 80% of the time has been 
accepted as standard for good adherence and was applied 
in most studies [23]. Nonadherence strongly depends on 
drug classes used and vary from 7 to 72% with an over-
all nonadherence rate around roughly 35%. The 43% of 
IBD patients not receiving any IBD-specific treatment in 
our cohort are close to the reported overall nonadherence 
rate. Our database did not allow to answer the question 
how many patients were newly diagnosed with IBD dur-
ing the hospitalization. As for the 37% of IBD patients not 
having had any diagnostic and/or follow-up procedures in 
the year before IBD-related hospitalization, this number 
compares well with the 43% of patients not being treated 
with IBD-specific drugs. It is crucial to remember that 
IBD patients need regular follow-up visits even if they are 
asymptomatic as also patients in clinical remission might 
have ongoing endoscopically active disease that is asso-
ciated with bowel damage in the long term [22,24–26]. 
We observed that IBD patients who were followed by gas-
troenterologists received more frequently IBD drug treat-
ment (5-ASA, steroids, immunomodulators, and biologics) 
when compared with patients who were followed by pri-
mary care physicians. Apparently, there exists a difference 
in treatment patterns between gastroenterologists and pri-
mary care physicians in the 12-month period before IBD-
related hospitalization. However, our data do not allow to 
judge if this observation is related to differences in disease 
activity.
IBDs are known to be associated with important health 
resource utilization and associated costs [27,28]. In a sys-
tematic review comparing the costs of Crohn’s disease 
in the United States with costs in Western industrialized 
countries, researchers found that estimated direct annual 
costs were US$ 18 022–18 932 for Crohn’s disease patients 
in the United States and EUR 2898–6960 in other Western 
countries [29]. Of note, the differences in healthcare sys-
tems between various countries somehow limits direct 
comparisons. Median costs for healthcare consumption in 
the year before IBD-related hospitalization was EUR 4320 
with comparable costs for Crohn’s disease and ulcerative 
colitis patients. IBD drugs and specialist consultations 
each accounted for one third of total costs. As such, these 
costs are much lower compared with the costs that were 
generated during an IBD-related hospitalization and an 
observation period of one year (starting with the day of 
the index hospitalization) where total median costs were 
approximately EUR 14 230 for ulcerative colitis patients 
and EUR 20 000 for Crohn’s disease patients [30]. In hos-
pitalized IBD patients, about one-third of total costs was 
attributed to inpatient costs, whereas IBD drugs were the 
highest cost position for outpatients [29]. Several studies 
reported on a shift from inpatient to outpatient costs in 
recent years, which seems closely related to the introduc-
tion of new medical therapies such as biologics, which are 
used more frequently in Crohn’s disease than in ulcerative 
colitis patients [7,13].
Our study has several strengths and also some limi-
tations. The first strength is that our analysis relies on a 
large study population which enabled us to provide an 
overview of the IBD situation in Switzerland. This is in 
contrast to data from the Swiss IBD cohort study where 
patients are included in 80% by gastroenterologists work-
ing in hospital. As such, our sample can be regarded as 
population-based. We think that our data are represent-
ative of the situation in Switzerland, as Helsana covers 
15% of the entire Swiss population. Second, our data are 
innovative as this is the first study to provide a detailed 
analysis of the use of IBD-specific drugs and healthcare 
utilization in the 12 months before IBD-related hospi-
talization. Third, data were not collected by means of 
self-report and, as such, results were not skewed due to an 
inherent recall bias. A fourth strength is that claims data 
in hospitalized IBD patients allow us to stratify into ulcer-
ative colitis and Crohn’s disease which stands in contrast 
to Swiss claims data from the outpatient setting. Based on 
this, we were able to reveal significant differences between 
the two entities with regards to the utilization of IBD-
specific drugs but also healthcare utilization. As a first 
limitation, data did not allow us to answer the question 
of how many patients were newly diagnosed with IBD 
when they were hospitalized. As such, we cannot judge the 
proportion of newly diagnosed IBD patients was among 
those who did not receive any IBD-specific drug during 
the 12-month period before hospitalization. Second, we 
have no information on disease duration and disease 
course. Both factors could have a direct impact on drug 
use, healthcare utilization, and costs. However, following 
legal obligations, health insurances are not allowed to 
capture these data.
In conclusion, nearly half of IBD patients did not receive 
any IBD-specific treatment and close to 40% had no diag-
nostic procedures in the 12 months before hospitalization. 
The frequency of use of 5-ASA, steroids, and immuno-
modulators typically increased in the three months before 
hospitalization. Median annual costs before IBD-related 
hospitalization were about EUR 4300. Our data imply 
that a relevant proportion of IBD patients is not benefiting 
from adequate diagnostic and therapeutic measures. With 
the ultimate goal of improving quality of care and associ-
ated health-related outcomes, measures should be taken 
to timely diagnose and treat IBD outpatients and monitor 
their adherence to treatment.
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